AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06050291 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fixed-Dose Combination (FDC) Tablet
Description: Obicetrapib/Ezetimibe FDC tablet
Study NCT04912622 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Clinical Trial
Description: Retinal image acquisition with Cellularis version 2.0
Study NCT06720168 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Erythritol air polisher
Description: Dental prophylaxis with erythritol air polisher in patients with dental black stain
Study NCT06720168 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dental prophylaxis with ultrasonic treatment
Description: Dental prophylaxis with ultrasonic treatment in patients with dental black stain
Study NCT06740669 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Virtual reality glasses (VR) application
Description: It will be evaluated at 1 and 6 hours after the Caesarean section and a relaxing video called Relaxation (https://www.youtube.com/watch?v=H1iboKia3AQ, a video containing nature scenes accompanied by nature sounds) will be shown for a maximum of 20 minutes through virtual reality glasses (Toker and Gökduman Keleş, 2024).
Study NCT06740669 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Those who are applied expressive touch
Description: Expressive touch does not require any preparation other than warming the hands to the same temperature as the body temperature. During expressive touch practice; the parts of the body that are touched the most are the hands, arms, forehead, hair and shoulders. The hands are massaged during the touch and the arms and shoulders are lightly touched before and after the massage, so that the expressive touch made on the hands is effective (Pinar and Demirel, 2021; Routasalo, 1999) After the evaluation, the researcher will apply expressive touch to one of the mother's hands for an average of 15-20 minutes
Study NCT06213519 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-1, Oxaliplatin sintilimab HIPEC
Description: 1. Exploratory laparoscopy or laparotomy~2. SOX regimen (oxaliplatin 100mg/m2, d1, S-1 BSA\<1.25m2 40mg, twice a day; 1.25m2 ≤ BSA \< 1.5m2 50mg, twice a day; BSA ≥ 1.5m2 60mg, twice a day; d1-14) chemotherapy combined with sintilimab (200mg, d1), once every three weeks.~3. In the first cycle, HIPEC (paclitaxel 80 mg/m2, d1-d3) will be administrated,~4. In the second and third cycles, HIPEC or intraperitoneal chemotherapy (paclitaxel 80 mg/m2, d1) will be administrated according to the patient's condition.~5. Another 3-cycle SOX regimen of systemic chemotherapy.~6. After the end of 6 cycles, maintain treatment with a combination of S-1 and sintilimab until disease progression or intolerable toxicity.
Study NCT04169451 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: Women will be randomized to the group with ovarian stimulation with letrozole or the group without stimulation.
Study NCT05483114 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Accuracy of indirect bonding of self-ligating brackets made with polyvinylsiloxane transfers
Description: The uppethat consists of positioning brackets on a study model and they will be extended to the patient's mouth. .r hemiarch of each patient will be randomly placed to be cemented with a transfer tray made of polyvinylsiloxane thermal glue, by means of the indirect technique
Study NCT05483114 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Accuracy of indirect bonding of self-ligating brackets made with thermal glue transfers
Description: The uppethat consists of positioning brackets on a study model and they will be extended to the patient's mouth. .r hemiarch of each patient will be randomly placed to be cemented with a transfer tray made of polyvinylsiloxane thermal glue, by means of the indirect technique
Study NCT01151514 — intervention group
Intervention type: OTHER
Intervention: Nephrologist referral
Description: Nephrologist specialty, renal replacement therapy
Study NCT05278494 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dextromethorphan Hydrobromide
Description: PO
Study NCT05175300 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prosthesis with CoPXE couple.
Description: Prosthesis with a second-generation ceramic-on-highly cross-linked polyethylene (CoPXE) couple.
Study NCT05175300 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Prosthesis with CoC torque.
Description: Prosthesis with ceramic-on-ceramic (CoC) torque.
Study NCT04913623 — intervention group
Intervention type: PROCEDURE
Intervention: Hip Replacement
Description: The hip replacement surgery is when a damaged hip is replaced with artificial one
Study NCT05234775 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lerodalcibep
Description: 300 mg of each drug given SC as single dose
Study NCT05234775 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lerodalcibep
Description: 300 mg of each drug given SC as single dose
Study NCT06386198 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health Advocate
Description: The Health Advocate intervention will include helping pediatric liver transplant recipients and their families address unmet household social needs (e.g., food insecurity), improve patient-provider communication, and enhance care coordination.
Study NCT05612841 — intervention group
Intervention type: OTHER
Intervention: data collection
Description: data collection from drug-drug interaction between anti-cancer treatment and and other medications
Study NCT05278494 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: PO
Study NCT04471571 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resin infiltration and microabrasion for MIH-affected incisors
Description: MIH-affected incisors will be treated with microabrasion followed by resin infiltration as a combined treatment
Study NCT04471571 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Resin infiltration for MIH-affected incisors
Description: MIH-affected incisors will be treated with resin infiltration alone
Study NCT06740669 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Focus
Description: . The researcher mother will be asked to focus on her baby for 10 minutes (Kiliçli Id and Zeyneloglu Id, 2024; Vamour et al., 2019).
Study NCT06480435 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chest physical Therapy
Description: Chest Percussion is a conventional method to clear airway and mobilize the thick mucus from the chest wall. Percussion can be applied by both manually and mechanically, but the mechanical percussion is more useful
Study NCT06480435 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Lungs squeezing technique
Description: It improves the oxygen saturation and lung volumes better than percussion.~This technique has two phases:~1. Squeezing phase~2. Release phase
Study NCT06301971 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emraclidine
Description: Oral solution/suspension
Study NCT05297110 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: atherolive
Description: In each study population, the patient will be assigned to one of two treatments (atherolive or placebo) using a computer-generated randomization list (1: 1 allocation). The investigator who has the randomization code is not involved in other study procedures and does not interact with participants. The study drug (atherol) will be prescribed at a dose of 400 mg, once a day for 3 months. The placebo will be prescribed identically.
Study NCT05297110 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: atherolive
Description: In each study population, the patient will be assigned to one of two treatments (atherolive or placebo) using a computer-generated randomization list (1: 1 allocation). The investigator who has the randomization code is not involved in other study procedures and does not interact with participants. The study drug (atherol) will be prescribed at a dose of 400 mg, once a day for 3 months. The placebo will be prescribed identically.
Study NCT06215794 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Rehabilitation therapy
Description: Rehabilitation therapy includes~1. Diet management: Avoiding consumption of irritant foods and beverages, such as spicy foods, caffeine, alcohol, and acidic foods. Controlling portion sizes and meal timing, and adopting smaller, more frequent meals.~2. Lifestyle adjustments: Avoiding lying down or bending immediately after meals, maintaining a sitting or upright position for at least 2 hours. Adjusting sleeping positions by elevating the head of the bed to reduce nighttime acid reflux. Avoiding excessive exertion and managing stress levels.~3. Rehabilitation training: Strengthening the control of esophageal and gastric muscles through rehabilitation exercises to improve the function of the gastroesophageal sphincter and prevent gastric fluid reflux.
Study NCT06215794 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Rehabilitation therapy
Description: Rehabilitation therapy includes~1. Diet management: Avoiding consumption of irritant foods and beverages, such as spicy foods, caffeine, alcohol, and acidic foods. Controlling portion sizes and meal timing, and adopting smaller, more frequent meals.~2. Lifestyle adjustments: Avoiding lying down or bending immediately after meals, maintaining a sitting or upright position for at least 2 hours. Adjusting sleeping positions by elevating the head of the bed to reduce nighttime acid reflux. Avoiding excessive exertion and managing stress levels.~3. Rehabilitation training: Strengthening the control of esophageal and gastric muscles through rehabilitation exercises to improve the function of the gastroesophageal sphincter and prevent gastric fluid reflux.
Study NCT06215794 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Glossopharyngeal Nerve Block
Description: The patient lies supine without a pillow, turns the head to the contralateral side of the block, and at the midpoint of the line connecting the angle of the mandible with the mastoid process (the styloid process), the skin is disinfected, and a 22-gauge, 3.8 cm puncture needle is loaded onto a 5 mL syringe. The puncture needle is inserted perpendicularly to the skin surface at the styloid process, and advanced through the skin and subcutaneous tissue until it contacts the bone of the styloid process. The puncture needle is then retracted and advanced anteriorly beyond the styloid process by 0.5-1.0 cm. When no blood or cerebrospinal fluid is aspirated, the blocking drug can be injected \[20 g/L lidocaine injection\].
Study NCT05788107 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HLX51
Description: anti-OX40 tetravalent agonistic humanized monoclonal antibody
Study NCT06135116 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Flow Cytometric Detection of Regulatory T Cells and Cytokines analysis by ELISA
Description: Gingival crevicular fluid samples collection After removing supragingival plaque, sampling sites were isolated by cotton rolls and dried using air syringe, GCF samples were collected by inserting standardized paper point in the sulcus/ pocket at the proximal-facial line angle of six preselected sites in each patient teeth . Fluid was sucked by paper points for 30 seconds. The samples were immediately placed inside graduated eppendorf vials containing 250µl phosphate-buffered saline (PBS), and transported to the laboratory for subsequent assays .~Blood Samples Collection From control and patient groups and under standard aseptic conditions, the peripheral blood was collected in Ethelene Diamine Tetra Acetic Acid (EDTA) coated vacutainer tubes (K2 EDTA) 5.4mg (BD vacutainer) and transferred immediately to flow cytometric analysis lab.
Study NCT06738849 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EkiYou V2
Description: Use of a Digital Therapy in the form of a mobile application that helps users to evaluate their daily bolus and basal insulin needs, and that adjusts at weekly basis their insulin to carb ratios, correction factor and basal dose.~The device includes the following features to participants:~* Carbohydrate counting through an extensive food database with more than 200k items.~* Bolus calculation based on their meal, physical activity and blood glucose.~* Bolus correction advice.~* Long-acting insulin reminders and automatic periodic titration.~* Insulin-to-carb ratios and correction factor automatic adjustment.
Study NCT05776927 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QVM149
Description: QVM149: Indacaterol as acetate 150 µg / glycopyrronium as bromide 50 µg / mometasone furoate 160 µg od delivered via Breezhaler®
Study NCT05776927 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Salmeterol Xinafoate / Fluticasone Propionate
Description: Salmeterol Xinafoate 50 μg / Fluticasone Propionate 500 μg bid delivered via Girohaler®
Study NCT05776927 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo to QVM149
Description: Placebo to QVM149: 150 μg Indacaterol Acetate / 50 μg Glycopyrronium Bromide / 160 μg Mometasone Furoate od delivered via Breezhaler®
Study NCT05776927 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to Salmeterol Xinafoate / Fluticasone Propionate
Description: Placebo to Salmeterol Xinafoate 50 μg / Fluticasone Propionate 500 μg bid delivered via Girohaler®
Study NCT05776927 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Run-In Medication
Description: Salmeterol Xinafoate 50 μg / Fluticasone Propionate 250μg bid delivered via Girohaler® or equivalent DPI device
Study NCT05776927 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Run-In Medication
Description: Salmeterol Xinafoate 50 μg / Fluticasone Propionate 250μg bid delivered via Girohaler® or equivalent DPI device
Study NCT05776927 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rescue Medication
Description: Salbutamol 100μg / Albuterol 90μg
Study NCT05776927 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rescue Medication
Description: Salbutamol 100μg / Albuterol 90μg
Study NCT05776927 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Concept 1 Device
Description: Concept1 (Breezhaler) used for QVM149 and placebo delivery
Study NCT05776927 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Concept 1 Device
Description: Concept1 (Breezhaler) used for QVM149 and placebo delivery
Study NCT05776927 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Girohaler
Description: Girohaler for Comparator and Placebo delivery.
Study NCT05776927 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Girohaler
Description: Girohaler for Comparator and Placebo delivery.
Study NCT04161599 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cefuroxime (750mg) I.V
Description: Extra dosage
Study NCT04161599 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cefuroxime (750mg) I.V
Description: Extra dosage
Study NCT04161599 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Colonic Surgery
Description: Colonic Surgery
Study NCT04161599 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Colonic Surgery
Description: Colonic Surgery
Study NCT04161599 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cefuroxime 750mg oral
Description: Oral prophylaxis
Study NCT04161599 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cefuroxime 750mg oral
Description: Oral prophylaxis
Study NCT04161599 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metronidazole 250 MG Oral Tablet [Flagyl]
Description: Oral prophylaxis
Study NCT04161599 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metronidazole 250 MG Oral Tablet [Flagyl]
Description: Oral prophylaxis
Study NCT04161599 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metronidazole 1 g Intravenous
Description: IV prophylaxis
Study NCT04161599 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metronidazole 1 g Intravenous
Description: IV prophylaxis
Study NCT04161599 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cefuroxime 1,5 g Intravenous
Description: IV prophylaxis
Study NCT04161599 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cefuroxime 1,5 g Intravenous
Description: IV prophylaxis
Study NCT04161599 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium picosulfate, light magnesium oxide, anhydrous citric acid 10 mg/3.5 g/10.97 g Oral
Description: Laxative for bowel cleansing
Study NCT04716413 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dsuvia
Description: Subject will receive up to 2 doses of Dsuvia. The first dose will be intra-op and the second dose will be post-op (if needed)
Study NCT06336122 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Peer Coach Training - Weekly
Description: Peer participants will be contacted by peer coaches on a weekly basis.
Study NCT06336122 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Peer Coach Training - Biweekly
Description: Peer participants will be contacted by peer coaches on a bi-weekly basis
Study NCT05921422 — intervention group
Intervention type: OTHER
Intervention: Cognitive assessment
Description: All participants will receive cognitive assessment with a core battery (CPCog) and a supplemental battery.~The core battery includes standardized tests of general cognitive functioning (intelligence) and visual-spatial abilities, as well as a questionnaire on executive functioning in daily life. The supplemental battery assesses attention, executive functioning, memory, fatigue, and symptoms of mental health issues (including symptoms of anxiety, depression, and attention deficit hyperactivity disorder/ADHD).
Study NCT06002256 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Mostafa Maged maneuver
Description: While the patient is on the lithotomy position , The first step in the Mostafa Maged maneuveur step is placing the right hand to the posterior fornix of vaginal canal trying to put pressure on the cervix and the lower part of uterus compressing the anterior and posterior walls of the lower uterine segment. The second point is placing the left hand over the fundus of the uterus and the posterior wall of the uterus from the abdominal part of the pregnant mother (the side of the abdominal skin). The third step is trying to grasp the whole uterus by the two hands abdominally and vaginally against the symphysis pubis as if the uterus is containing or surrounding the symphysis pubis bone, and in this way, getting the anterior and posterior walls of the uterus against each other (compression achieved)
Study NCT06002256 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Bimanual uterine compression
Description: the clinician places one hand on the abdomen and the other hand inside the vagina then compresses the uterus between the two hands.
Study NCT05565352 — intervention group
Intervention type: DRUG
Intervention: Ketamine Hydrochloride
Description: Ketamine, a N-methyl-D-aspartate (NMDA) receptor antagonist has been used for general anesthesia since the 1970s, however, reports and trials by the end of the twentieth century and onward using subanesthetic doses suggested robust and rapid antidepressant and anti-suicidal effects. Ketamine is available as a 50/50 racemic mixture of enantiomers (S)-ketamine and (R)-ketamine.Ketamine will be infused (slow IV infusions of ketamine (0.5 mg/kg) over 40 minutes) twice weekly over a period of 4 weeks) Ketamine will be given in intranasal spray twice weekly over a period of 4 weeks Ketamine will be given orally (solution 2.0mg/kg, 2.5mg/kg) twice weekly over a period of 4 weeks.
Study NCT06240988 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Modified Constraint Induced Movement Therapy
Description: Modified Constraint Induced Movement Therapy
Study NCT06240988 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Motor Imagery Technique
Description: Motor Imagery Technique
Study NCT04558489 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: IPR + GMI
Description: The IPR + GMI intervention aims to impact reported hopelessness, attitudes to treatment, and view of self as changeable as well as targets treatment attendance and utilization.
Study NCT06645821 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EVO101
Description: EVO101 topical cream 0.1%
Study NCT05045404 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Poziotinib Hydrochloride
Description: 1429757-68-5, HM781-36B, NOV-1201 Hydrochloride, NOV120101 Hydrochloride, Poziotinib HCl, POZIOTINIB HYDROCHLORIDE~Given PO
Study NCT05045404 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 1429757-68-5, HM781-36B, NOV-1201 Hydrochloride, NOV120101 Hydrochloride, Poziotinib HCl, POZIOTINIB HYDROCHLORIDE
Description: Biological/Vaccine Ramucirumab 947687-13-0, anti-VEGFR-2 fully human monoclonal antibody IMC-1121B, Anti-VEGFR-2 Fully Human Monoclonal Antibody IMC-1121B, Cyramza, IMC-1121B, IMC-1121B, LY3009806, Monoclonal Antibody HGS-ETR2, ramucirumab, RAMUCIRUMAB~Given IV
Study NCT06513156 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Integrated Infectious Diseases and Medication for Opioid Use Disorder Clinic (IC)
Description: Integrated medication for opioid use disorder and infectious disease care provided into single appointment either in person or via telemedicine with a minimum of monthly appointments for 6 months.
Study NCT06513156 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: NavSTAR-CHOICE (NS)
Description: Patient-centered social support intervention including motivational interviewing and patient navigation designed to overcome the barriers in accessing the recommended follow-up opioid use disorder treatment and medical care services for 6 months.
Study NCT04767854 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: OA school
Description: Patient education according to guidelines, with information about e.g. disease progression, symptoms, treatment, exercise, self-care techniques and dietary information